Recombinant protein · Agonist of growth hormone receptor (GHR) · developed by Novo Nordisk
Somapacitan is a long-acting human growth hormone analog that binds the dimeric growth hormone receptor on target cells, triggering intracellular signal transduction, including IGF-1 production in the liver. It is given once weekly by subcutaneous injection and is studied in pediatric growth disorders, including growth hormone deficiency in children.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03811535 | Phase 3 | Growth Hormone Deficiency in Children | Completed | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Growth Hormone Deficiency in Children
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →